Treatment outcomes in multidrug resistant tuberculosis

New England Journal of Medicine

Volumn 375, Issue 11, 2016, Pages 1103-1105

  Günther, Gunar ^a   Lange, Christoph ^a   Alexandru, Sofia ^b   Altet, Neus ^c   Avsar, Korkut ^d   Bang, Didi ^e   Barbuta, Raisa ^f   Bothamley, Graham ^g   Ciobanu, Ana ^h   Crudu, Valeriu ^h   Danilovits, Manfred ⁱ   Dedicoat, Martin ^j   Duarte, Raquel ^k   Gualano, Gina ^l   Kunst, Heinke ^m   De Lange, Wiel ⁿ   Leimane, Vaira ^o   Magis Escurra, Cecile ^p   McLaughlin, Anne Marie ^q   Muylle, Inge ^r   Polcová, Veronika ^s   Popa, Christina ^t   Rumetshofer, Rudolf ^u   Skrahina, Alena ^u   Solodovnikova, Varvara ^u   Spinu, Victor ^s   Tiberi, Simon ^v   Viiklepp, Piret ^w   Van Leth, Frank ^x   more..

^a RESEARCH CENTER BORSTEL   (Germany)

^b Institute of Phtisiopneumology   (Moldova)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^e STATENS SERUM INSTITUT   (Denmark)

^f Balti Municipal Hospital   (Moldova)

^g HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^h TARTU UNIVERSITY HOSPITAL   (Estonia)

ⁱ UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF PORTO   (Portugal)

^k NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^l QUEEN MARY S HOSPITAL   (United Kingdom)

^m UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁿ RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^o RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^p ST JAMES S HOSPITAL   (Ireland)

^q Microbiology Lab   (Belgium)

^r FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^s MDR TB Centre   (Romania)

^t OTTO WAGNER HOSPITAL   (Austria)

^u Republican Scientific and Practical Center for Pulmonology and Tuberculosis   (Belarus)

^v BARTS HEALTH NHS TRUST   (United Kingdom)

^w NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^x AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

DRUG TREATMENT FAILURE; HUMAN; INCIDENCE; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; ISOLATION AND PURIFICATION; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

HUMANS; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84988378181     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1603274     Document Type: Letter

References (5)

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015. Geneva: World Health Organization, 2015.
2. Definitions and reporting framework for tuberculosis-2013 revision. Geneva: World Health Organization, 2013.
3. Günther G, van Leth F, Alexandru S, et al. Multidrug-resis-tant tuberculosis in Europe, 2010-2011. Emerg Infect Dis 2015; 21:409-16.
4. Günther G, van Leth F, Altet N, et al. Beyond multidrug-re-sistant tuberculosis in Europe: a TBNET study. Int J Tuberc Lung Dis 2015;19:1524-7.
5. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2015; 3: 201-9.